Steven Christopher Gilman

US Patent:

7411057, Aug 12, 2008

Filed:

May 12, 2005

Appl. No.:

11/128900

Inventors:

Douglas C Hanson - Niantic CT, US
Mark J Neveu - Hartford CT, US
Eileen E Mueller - Old Lyme CT, US
Jeffrey H Hanke - Reading MA, US
Steven C Gilman - Cambridge MA, US
C. Geoffrey Davis - Burlingame CA, US
Jose R Corvalan - Foster City CA, US

Assignee:

Amgen Fremont Inc. - Fremont CA
Pfizer Inc. - New York NY

International Classification:

C07H 21/04
C12P 21/08
C12N 1/21
C12N 5/10
C12N 15/11

US Classification:

536 2353, 536 231, 536 235, 435 691, 4352523, 4353201, 435455

Abstract:

In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.

US Patent:

7807797, Oct 5, 2010

Filed:

Oct 31, 2007

Appl. No.:

11/981771

Inventors:

Douglas Charles Hanson - Niantic CT, US
Mark Joseph Neveu - Hartford CT, US
Eileen Elliott Mueller - Old Lyme CT, US
Jeffrey Herbert Hanke - Reading MA, US
Steven Christopher Gilman - Cambridge MA, US
C. Geoffrey Davis - Burlingame CA, US
Jose Ramon Corvalan - Foster City CA, US

Assignee:

Amgen Fremont Inc. - Fremont CA
Pfizer Inc. - New York NY

International Classification:

C07K 16/00
A61K 39/395

US Classification:

5303881, 4241411

Abstract:

In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.

US Patent:

7824679, Nov 2, 2010

Filed:

Oct 31, 2007

Appl. No.:

11/981810

Inventors:

Douglas Charles Hanson - Niantic CT, US
Mark Joseph Neveu - Hartford CT, US
Eileen Elliott Mueller - Old Lyme CT, US
Jeffrey Herbert Hanke - Reading MA, US
Steven Christopher Gilman - Cambridge MA, US
C. Geoffrey Davis - Burlingame CA, US
Jose Ramon Corvalan - Foster City CA, US

Assignee:

Amgen Fremont Inc. - Fremont CA
Pfizer Inc. - New York NY

International Classification:

A61K 39/395

US Classification:

4241421

Abstract:

In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.

US Patent:

8143379, Mar 27, 2012

Filed:

Oct 31, 2007

Appl. No.:

11/981824

Inventors:

Douglas Charles Hanson - Niantic CT, US
Mark Joseph Neveu - Hartford CT, US
Eileen Elliott Mueller - Old Lyme CT, US
Jeffrey Herbert Hanke - Reading MA, US
Steven Christopher Gilman - Cambridge MA, US
C. Geoffrey Davis - Burlingame CA, US
Jose Ramon Corvalan - Foster City CA, US

Assignee:

Amgen Fremont Inc. - Fremont CA
Pfizer Inc. - New York NY

International Classification:

C07K 16/00
A61K 39/395

US Classification:

53038815, 4241421

Abstract:

In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.

US Patent:

8491895, Jul 23, 2013

Filed:

Feb 17, 2012

Appl. No.:

13/399448

Inventors:

Douglas Charles Hanson - Niantic CT, US
Mark Joseph Neveu - Hartford CT, US
Eileen Elliott Mueller - Old Lyme CT, US
Jeffrey Herbert Hanke - Reading MA, US
Steven Christopher Gilman - Cambridge MA, US
C. Geoffrey Davis - Burlingame CA, US
Jose Ramon Corvalan - Foster City CA, US

Assignee:

Amgen Fremont Inc. - Thousand Oaks CA
Pfizer Inc. - New York NY

International Classification:

A61K 39/395

US Classification:

4241301

Abstract:

In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.

US Patent:

20150104409, Apr 16, 2015

Filed:

Oct 20, 2014

Appl. No.:

14/518990

Inventors:

- THOUSAND OAKS CA, US
- NEW YORK NY, US
Eileen Elliott Mueller - Old Lyme CT, US
Jeffrey Herbert Hanke - Reading MA, US
Steven Christopher Gilman - Cambridge MA, US
C. Geoffrey Davis - Auburn CA, US
Jose Ramon Corvalan - Foster City CA, US

International Classification:

C07K 16/28
A61K 39/395

US Classification:

424 851, 5303879, 5303873, 4241391, 536 2353, 514 44 R, 800 13, 800298, 435331, 435 696, 4353201

Abstract:

In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.

US Patent:

20140099325, Apr 10, 2014

Filed:

Jun 18, 2013

Appl. No.:

13/920590

Inventors:

- New York NY, US
- Thousand Oaks CA, US
Eileen Elliott Mueller - Old Lyme CT, US
Jeffrey Herbert Hanke - Reading MA, US
Steven Christopher Gilman - Cambridge MA, US
C. Geoffrey Davis - Burlingame CA, US
Jose Ramon Corvalan - Foster City CA, US

International Classification:

C07K 16/28

US Classification:

4241561, 53038885, 435 696, 536 2353, 4353201, 514 44 R, 800 13, 800298, 4353441, 5303873, 435 703

Abstract:

In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.